The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pathogenetic mechanisms of muscle-specific ribosomes in dilated cardiomyopathy
Open accessPreprint — published as 10.1038/s44161-025-00761-8
Abstract
The heart employs a specialized ribosome in its muscle cells to translate genetic information into proteins, a fundamental adaptation with an elusive physiological role 1–3 . Its significance is underscored by the discovery of neonatal patients suffering from often fatal heart failure caused by severe dilated cardiomyopathy when both copies of the gene RPL3L are mutated 4–9 . RPL3L is a muscle-specific paralog 1–3 of the ubiquitous ribosomal protein L3 (RPL3), which makes the closest contact of any protein to the ribosome’s RNA-based catalytic center 10 . RPL3L -linked heart failure represents the only known human disease associated with tissue-specific ribosomes, yet the underlying pathogenetic mechanisms remain poorly understood. Intriguingly, disease is linked to a large number of mostly missense variants in RPL3L , and RPL3L -knockout resulted in no severe heart defect in either human or mice 3, 11–13 , challenging the prevailing view that autosomal recessive diseases are caused by loss-of-function mutations. Here, we report three new cases of RPL3L -linked severe neonatal heart failure and present a unifying pathogenetic mechanism by which a large number of variants in the muscle-specific ribosome led to disease. Specifically, affected families often carry one of two recurrent toxic gain-of-function variants alongside a family-specific putative loss-of-function variant. While the non-recurrent variants often trigger partial compensation of RPL3 similar to Rpl3l -knockout mice, both recurrent variants exhibit increased affinity for the RPL3/RPL3L chaperone GRWD1 14–16 and 60S biogenesis factors, sequester 28S rRNA in the nucleus, disrupt ribosome biogenesis, and trigger severe cellular toxicity that extends beyond the loss of ribosomes. These findings provide critical insights for genetic screening and therapeutic development of neonatal heart failure. Our results suggest that gain-of-toxicity mechanisms may be more prevalent in autosomal recessive diseases, and a combination of gain-of-toxicity and loss-of-function mechanisms could underlie many diseases involving genes with paralogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Flagged first, then by citations
Research works printed but not linked: 65
- 10.1006/geno.1996.0538 · DOI
- 10.1002/jcp.25294 · DOI
- 10.1038/s41467-023-37838-6 · DOI
- 10.1007/s00439-020-02188-6 · DOI
- Das, B.B. , Gajula, V. , Arya, S. & Taylor, M.B. Compound Heterozygous Missense Variants in RPL3L Genes Associated with Severe Forms of Dilated Cardiomyopathy: A Case Report and Literature Review. Children (Basel) 9 (2022). · DOI
- Nannapaneni, H. et al. Further Evidence of Autosomal Recessive Inheritance of RPL3L Pathogenic Variants with Rapidly Progressive Neonatal Dilated Cardiomyopathy. J Cardiovasc Dev Dis 9 (2022). · DOI
- 10.1161/CIRCGEN.120.002969 · DOI
- Bajpai, A.K. et al. Exploring the Regulation and Function of Rpl3l in the Development of Early-Onset Dilated Cardiomyopathy and Congestive Heart Failure Using Systems Genetics Approach. Genes (Basel) 15 (2023). · DOI
- Yang, Q. et al. Novel compound heterozygous variants in the RPL3L gene causing dilated cardiomyopathy type-2D: a case report and literature review. BMC Med Genomics 16, 127 (2023). · DOI
- 10.1261/rna.2165803 · DOI
- 10.1093/nar/gkad121 · DOI
- Grimes, K.M. et al. Rpl3l gene deletion in mice reduces heart weight over time. Frontiers in Physiology 14 (2023). · DOI
- Pillet, B. et al. Dedicated chaperones coordinate co-translational regulation of ribosomal protein production with ribosome assembly to preserve proteostasis. Elife 11 (2022). · DOI
- 10.1128/MCB.21.4.1260-1271.2001 · DOI
- 10.1016/S0960-9822(01)00584-X · DOI
- 10.1016/j.cell.2015.05.026 · DOI
- 10.1016/j.tibs.2021.07.001 · DOI · Paper page
- 10.1038/s41467-022-33263-3 · DOI
- 10.1016/j.molcel.2018.07.018 · DOI · Paper page
- 10.1016/j.cell.2017.05.022 · DOI · Paper page
- 10.1016/j.molcel.2017.05.021 · DOI
- 10.1038/s41586-022-05508-0 · DOI
- Zou, Q. et al. Proteostasis regulated by testis-specific ribosomal protein RPL39L maintains mouse spermatogenesis. iScience 24, 103396 (2021). · DOI
- 10.1016/j.molcel.2007.02.015 · DOI
- 10.1101/gr.6.6.525 · DOI
- 10.1038/s41586-020-2797-4 · DOI · Paper page
- 10.1126/science.aaz1776 · DOI · Paper page
- Milenkovic, I. et al. RPL3L-containing ribosomes modulate mitochondrial activity in the mammalian heart. bioRxiv, 2021.2012.2004.471171 (2021). · DOI
- 10.1161/CIRCRESAHA.116.309396 · DOI · Paper page
- 10.1038/s41569-019-0284-0 · DOI
- 10.1056/NEJM200012073432304 · DOI · Paper page
- 10.1126/science.1168979 · DOI
- 10.1161/CIRCRESAHA.116.309386 · DOI
- 10.1001/jama.296.15.1867 · DOI
- 10.1038/s42003-018-0068-9 · DOI
- 10.1126/science.adg7492 · DOI · Paper page
- 10.1038/s41586-024-07050-7 · DOI
- 10.1038/s41586-023-06957-x · DOI · Paper page
- 10.1038/s41586-018-0579-z · DOI · Paper page
- 10.1038/s41586-024-07556-0 · DOI · Paper page
- 10.15252/embj.2022112699 · DOI
- 10.1038/s41569-019-0315-x · DOI
- 10.1016/j.yjmcc.2005.03.003 · DOI · Paper page
- 10.1038/s41467-023-41799-1 · DOI
- 10.1161/circresaha.119.315862 · DOI · Paper page
- 10.1093/cvr/cvab115 · DOI
- 10.1093/nar/gkac724 · DOI
- 10.1016/j.celrep.2022.110353 · DOI
- 10.1016/j.celrep.2022.110640 · DOI
- 10.1261/rna.7200205 · DOI
- 10.1016/j.molcel.2013.08.011 · DOI
- 10.1038/s41467-018-07783-w · DOI
- 10.1093/nar/gkp806 · DOI
- 10.1073/pnas.2208960120 · DOI
- 10.1007/s10875-024-01758-x · DOI
- 10.1126/science.aax3649 · DOI · Paper page
- 10.1038/s41467-022-31686-6 · DOI
- 10.1093/molbev/msr111 · DOI
- 10.1038/s41586-019-1064-z · DOI · Paper page
- 10.1038/nature14580 · DOI
- 10.1371/journal.pgen.1006780 · DOI · Paper page
- 10.1016/j.cell.2019.05.010 · DOI
- 10.1038/s41592-020-00998-0 · DOI
- 10.1038/nmeth.2834 · DOI · Paper page
- 10.1038/s41592-019-0638-x · DOI
Metadata
- Authors
- Murphy, M. R., Ganapathi, M., Lee, T. M., Fisher, J. M., Patel, M. V., Jayakar, P., Buchanan, A., Rippert, A. L., Ahrens-Nicklas, R. C., Nair, D., Soni, R. K., Yin, Y., Yang, F., Reilly, M. P., Chung, W. K., & Wu, X.
- Affiliations
- Columbia University Irving Medical Center (US)
- Medical College of Wisconsin (US)
- Miami Children's Hospital (US)
- Illumina (United States) (US)
- Children's Hospital of Philadelphia (US)
- Division of Human Genetics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Herbert Irving Comprehensive Cancer Center (US)
- Boston Children's Hospital (US)
- Corresponding author
- Murphy, Michael R.
- Wu, Xuebing
- ORCID
- Venue
- Nature Cardiovascular Research
- Publisher
- openRxiv
- Published
- 2025-01-03
- Volume
- 5
- Issue
- 1
- Pages
- 51-66
- ISSN
- 2731-0590 (ISSN-L)
- PMC
- PMC12811116
- OpenAlex
- W7118251413
- Cited by
- 4
- References
- 1
- Citations by year
- 2026: 1 · 2025: 3
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Cardiovascular Research (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Funders
- American Heart Association (P30CA013696)
- Wellcome Trust
- Department of Biotechnology, Ministry of Science and Technology, India
- The Wellcome Trust DBT India Alliance (IA/CRC/20/1/600002)
- National Institutes of Health (1s10od020056-01, 1s10od030282-01a1, UL1TR001873)
- Irving Medical Center, Columbia University (P30-CA013696, UL1TR001873)
- National Heart, Lung, and Blood Institute (R01HL053392, S10OD020056, R01HL087000, R13HL087708, F31HL094100, R01HL171664)
- NIH Office of the Director
- National Cancer Institute (P30CA013696)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- dilated cardiomyopathy, ribosomal protein L3, ribosomal protein mutations, missense mutations, rRNA processing, ribosome biogenesis, heart failure, genotype-phenotype correlation, isogenic cell models, genetic screening
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review